AI Insight
Activists and leaders at a global HIV meeting criticized pharmaceutical company Gilead for failing to provide affordable access to lenacapavir, an HIV prevention drug, in Latin America. The criticism centers on pricing strategies that make the medication inaccessible to populations that need it most. Lenacapavir is a long-acting injectable drug that has shown promise as an HIV prevention tool.
Why it matters
Access to affordable HIV prevention medications is critical for controlling the epidemic, particularly in regions with limited healthcare resources. The pricing debate highlights ongoing tensions between pharmaceutical companies' profit margins and global public health needs, which directly affects HIV prevention efforts in vulnerable populations.
Understand the Science
Gilead is criticized for lack of affordable access to lenacapavir in Latin America
Source: Activists and leaders at global HIV meeting decry price of prevention drug